Inside the research
Medtronic plc
MDT Research profile · latest available data
Price overview
$88.64
▲ +0.85 (+1.0%)
| 52w hi | $101.97 |
|---|---|
| 52w lo | $72.50 |
| Vol | 13.05M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.58
| Short | +0.52 |
|---|---|
| Medium | +0.62 |
| Long | +0.62 |
computed 2026-09-27
Key fundamentals
Medtronic plc
Healthcare · Medical Devices
| Market cap | $113.38B |
|---|---|
| Enterprise value | $133.33B |
| Trailing P/E | 21.83x |
| Forward P/E | 13.84x |
| EV / EBITDA | 12.81x |
| P / S (ttm) | 3.02x |
| Profit margin | 13.9% |
| Return on equity | 10.6% |
| Revenue growth | +13.7% |
| Earnings growth | +40.7% |
| Debt / equity | 55.37 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.36 | |
| Sector | +0.08 | |
| Technical | +0.17 | |
| Earnings | +0.00 | |
| Sentiment | +0.42 |
macro × 1.00 · 2026-09-27
Business overview
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Risk Metrics
| Beta vs SPX | 0.37 |
|---|---|
| Corr SPX | 0.27 |
| Annual vol | 22.5% |
| Annual ret | +2.1% |
| Sharpe | 0.09 |
| Max DD | -30.0% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $108.00 |
|---|---|
| High / Low | $121.00 / $90.00 |
| Median | $110.00 |
| Analysts | 25 |
| Strong Buy | 4 | |
|---|---|---|
| Buy | 14 | |
| Hold | 11 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-04-22 | UBS | → Neutral |
| 2026-04-15 | Truist Securities | → Hold |
| 2026-04-13 | Mizuho | → Outperform |
| 2026-04-09 | Evercore ISI Group | → Outperform |
| 2026-04-07 | Citigroup | → Buy |
| 2026-04-06 | Evercore ISI Group | → Outperform |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-06-03 | Earnings Release, Exhibits | read |
| 2026-05-18 | Officer / Director Change, Exhibits | read |
| 2026-04-27 | Reg FD Disclosure, Exhibits | read |
| 2026-03-24 | Reg FD Disclosure | read |
| 2026-02-17 | Earnings Release, Exhibits | read |
| 2025-11-18 | Earnings Release, Exhibits | read |
| 2025-11-03 | Officer / Director Change | read |
| 2025-10-21 | Bylaws Amendment, Shareholder Vote… | read |
| 2025-09-29 | Material Agreement, Other Material Event… | read |
| 2025-09-16 | Reg FD Disclosure, Other Material Event… | read |
| 2025-08-19 | Earnings Release, Officer / Director Change… | read |
| 2025-06-23 | Officer / Director Change | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-03 | Martha Geoffrey | Chairman and CEO | Grant | 41.53K | — |
| 2026-08-03 | Pieton Thierry | EVP & Chief Financial Off | Grant | 11.54K | — |
| 2026-08-03 | Marinaro Michael | EVP, Pres MedSurg and Ame | Grant | 46.15K | — |
| 2026-08-03 | KIIL HARRY SKIP | EVP & President Cardiovas | Grant | 9.23K | — |
| 2026-08-03 | Thompson Kweli | EVP & President, Neurosci | Grant | 6.92K | — |
| 2026-08-03 | Quinn Michelle | EVP, GC and Secretary | Grant | 6.35K | — |
| 2026-08-03 | Blomquist Denise L. | Chief Accounting Officer | Grant | 2.34K | — |
| 2026-08-03 | Marinaro Michael | EVP, Pres MedSurg and Ame | Grant | 10.96K | — |
| 2026-08-03 | Walter Matthew R. | SVP, Chief HR Officer | Grant | 5.77K | — |
| 2026-07-31 | Walter Matthew R. | SVP, Chief HR Officer | Withheld for tax | 1.68K | $143.03K |
Flow & Concentration
| Insider 180d net | -$257.93K |
|---|---|
| Insider buys / sells | 0 / 1 |
| Insider bias | Neutral |
| 13F holders | 10 |
| Top-5 share | 92.0% |
| HHI | 4,041 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $5.01B | 63.40M |
| Norges Bank (Norway sovereign) | $1.08B | 13.78M |
| Citadel Advisors | $608.95M | 7.78M |
| Capital Research / Capital World | $583.85M | 7.46M |
| Fidelity / FMR LLC | $259.24M | 3.31M |
| AQR Capital Management | $258.13M | 3.30M |
| Renaissance Technologies | $247.81M | 3.17M |
| Millennium Management | $113.99M | 1.46M |
| Bridgewater Associates | $37.75M | 482.52K |
| T. Rowe Price Group | $592.71K | 7.58M |
As of 2026-06-30
Dividends
| Yield (TTM) | 1.60% |
|---|---|
| $ / share (TTM) | $1.42 |
| 5y CAGR | +4.4% |
Annual dividend per share
| 2021 | $2.47 |
|---|---|
| 2022 | $2.67 |
| 2023 | $2.75 |
| 2024 | $2.79 |
| 2025 | $2.83 |
| 2026 | $0.71 |
SEC Filings
The Long Run
FY 2015–2025 · 11 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $32.36B | +6.9% | |
| Gross profit | $5.66B | +12.3% | |
| Operating income | $5.14B | +3.0% | |
| Net income | $3.76B | +0.9% | |
| Cash from ops | $6.79B | +3.0% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $87.61 | $88.99 | $87.12 | $88.64 | 13.05M |
| Sep 24 | $89.74 | $90.28 | $88.46 | $88.51 | 10.96M |
| Sep 23 | $90.53 | $91.15 | $88.61 | $89.30 | 10.53M |
| Sep 22 | $92.51 | $92.67 | $90.55 | $90.77 | 14.06M |
| Sep 21 | $91.50 | $92.73 | $91.50 | $91.75 | 7.31M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →